Agilon Health (AGL) Cash & Equivalents (2020 - 2026)

Agilon Health (AGL) has 7 years of Cash & Equivalents data on file, last reported at $140.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 2.22% year-over-year to $140.0 million; the trailing twelve-month figure through Mar 2026 stood at $140.0 million (up 2.22% YoY), and the FY2025 full-year result was $173.7 million, down 7.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $140.0 million, down from $173.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.0 billion in Q1 2022 and bottomed at $107.6 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $171.7 million (2025), against an average of $289.4 million.
• The widest annual swing landed in 2022, when Cash & Equivalents surged 870.43%; it then slumped 76.88% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $465.3 million in 2022, then plunged by 76.88% to $107.6 million in 2023, then surged by 74.98% to $188.2 million in 2024, then slipped by 7.71% to $173.7 million in 2025, then fell by 19.41% to $140.0 million in 2026.
• The last three Cash & Equivalents figures came in at $140.0 million (Q1 2026), $173.7 million (Q4 2025), and $171.7 million (Q3 2025), per Business Quant data.

Peer Comparison